title: Three-year clinical outcome in the Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III) trial: a randomised comparison between sirolimus-eluting stent implantation and zotarolimus-eluting stent implantation for the treatment of total coronary occlusions.
abstract: OBJECTIVE
  Sirolimus-eluting stents (SES) have been shown to be superior to Endeavor zotarolimus-eluting stents (ZES) and comparable to Resolute ZES at eight-month angiography in patients treated for total coronary occlusions (TCO). This study investigated clinical outcome at three-year follow-up.
  
  
  RESULTS
  The PRISON III trial investigated the efficacy and safety of SES against ZES (Endeavor and Resolute) in two study phases. In the first phase, 51 patients were randomised to receive SES and 46 to Endeavor ZES. In the second phase, 103 and 104 patients were randomised to SES or Resolute ZES, respectively. Between one and three years there were only a few additional clinical events in all groups. As a result, the rates of target lesion revascularisation 12.2% vs. 19.6%, p=0.49, target vessel failure 14.3% vs. 19.6%, p=0.68, and definite or probable stent thrombosis 4.1% vs. 2.2% were comparable between SES and Endeavor ZES at three years. In the second study phase, the rates of target lesion revascularisation 10% vs. 5.9%, p=0.42, target vessel failure 10% vs. 7.9%, p=0.79 and definite or probable stent thrombosis 1.0% vs. 0% were similar between SES and Resolute ZES.
  
  
  CONCLUSIONS
  The present study demonstrated a low incidence of clinical events between one- and three-year follow-up with either SES compared to Endeavor ZES or SES versus Resolute ZES in patients treated for total coronary occlusions.
authors.affiliation: Department of Interventional Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands.
authors.forename: Koen
authors.initials: K
authors.lastname: Teeuwen
authors.forename: Ben J L
authors.initials: BJ
authors.lastname: Van den Branden
authors.forename: Jacques J
authors.initials: JJ
authors.lastname: Koolen
authors.forename: René J
authors.initials: RJ
authors.lastname: van der Schaaf
authors.forename: José P S
authors.initials: JP
authors.lastname: Henriques
authors.forename: Jan G P
authors.initials: JG
authors.lastname: Tijssen
authors.forename: Johannes C
authors.initials: JC
authors.lastname: Kelder
authors.forename: Paul H M J
authors.initials: PH
authors.lastname: Vermeersch
authors.forename: Benno J W M
authors.initials: BJ
authors.lastname: Rensing
authors.forename: Maarten J
authors.initials: MJ
authors.lastname: Suttorp
mesh_terms: D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000401:mortality; D054059:Coronary Occlusion / Q000188:drug therapy / Q000601:surgery*; D023903:Coronary Restenosis / Q000453:epidemiology; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology; D009204:Myocardial Revascularization / Q000706:statistics & numerical data; D062645:Percutaneous Coronary Intervention / Q000295:instrumentation; D012086:Reoperation; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D013927:Thrombosis / Q000453:epidemiology
chemical_list: D000903:Antibiotics, Antineoplastic; C489443:zotarolimus; D020123:Sirolimus